We are pleased to announce that the FDA has cleared our MagVita TMS Therapy system for the treatment of Major Depressive Disorder.
Low operating costs - due to no per-use fee - together with an easy administration and equal efficacy rates as other cleared devices makes the MagVita TMS Therapy system the optimal choice for both doctors and patients.
The MagVita TMS Therapy System is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
The MagVita TMS Therapy system was the first system to be cleared in the EU (in 2011) and has a proven track-record of treatment efficacy, usability, and quality.
Read the interviews with current users of the MagVita TMS Therapy system in our Newsletter, where you will also find exciting articles on pioneering research with TMS.
MagVenture is a medical device company specializing in non-invasive magnetic stimulation systems for depression treatment as well as for clinical examination and research in the areas of neurophysiology, neurology, cognitive neuroscience, rehabilitation, and psychiatry.
MagVenture strives to be the most dynamic and innovative supplier of transcranial magnetic stimulation solutions. Market feedback and inputs are continuously incorporated in our product development, and many "first mover" features and improvements have over the years been added in response to leading doctors' and researchers' ideas and requests.